Temozolomide plus pegylated liposomal doxorubicine is equal to temozolomide in the first-line treatment of patients with glioblastoma – Phase I/II-study
P Hau, C Schmid, B Hirschmann, C Kleinletzenberger, M Proescholdt, G Stockhammer, A Brawanski, M Hegi, U Bogdahn · Aktuelle Neurologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background: Temozolomide (Temodar® TMZ) recently showed promising efficacy in an EORTC trial on first-line therapy of glioblastoma (GBM). Pegylated liposomal doxorubicin (Caelyx® PEG-Dox) was evaluated in patients with recurrent glioblastoma (GBM) with an overall response rate of 40%. Therefore, a combination regimen seems promising. Methods: TMZ was given orally in a dose of 75mg/m2 daily during involved field radiotherapy (total dose, 60Gy) and 150–200mg/m2 on days 1–5 in 28 days starting 4 weeks after radiotherapy. PEG-Dox was administered in a dose-escalation regimen once prior to radiotherapy and on days 1…
